X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/18/2848135/0/en/Inventiva-announces-positive-results-from-the-Phase-II-LEGEND-Proof-of-Concept-study-combining-lanifibranor-with-empagliflozin-in-patients-with-MASH-NASH-and-T2D.html
https://www.globenewswire.com//news-release/2024/03/13/2845818/0/en/Inventiva-to-present-the-results-of-LEGEND-Phase-IIa-combination-trial-with-lanifibranor-and-empagliflozin-in-patients-with-MASH-NASH-and-T2D.html
https://www.globenewswire.com//news-release/2024/03/07/2842705/0/en/Inventiva-announces-that-screening-in-the-NATiV3-Phase-III-clinical-trial-evaluating-lanifibranor-in-NASH-has-resumed.html
https://www.globenewswire.com//news-release/2023/12/04/2790438/0/en/Inventiva-announces-the-positive-recommendation-of-the-third-DMC-of-the-Phase-III-clinical-trial-with-lanifibranor-in-patients-with-NASH.html
https://www.globenewswire.com//news-release/2023/11/06/2774457/0/en/Inventiva-announces-a-late-breaker-abstract-and-two-additional-abstracts-on-its-lead-compound-lanifibranor-at-the-AASLD-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/09/20/2746837/0/en/Inventiva-and-Hepalys-Pharma-Inc-announce-exclusive-licensing-agreement-to-develop-and-commercialize-lanifibranor-in-Japan-and-South-Korea.html
https://www.globenewswire.com/news-release/2023/06/13/2687682/0/en/Inventiva-announces-positive-topline-results-from-the-investigator-initiated-Phase-II-clinical-trial-evaluating-lanifibranor-in-patients-with-T2D-and-NAFLD.html
https://www.globenewswire.com/news-release/2023/05/25/2676684/0/en/Inventiva-announces-that-its-partner-Sino-Biopharm-received-IND-approval-from-the-NMPA-to-initiate-clinical-trial-with-lanifibranor-in-China.html
https://endpts.com/inventiva-changes-phase-iii-plans-for-nash-drug/
https://www.globenewswire.com/news-release/2022/09/21/2520615/0/en/Inventiva-and-Sino-Biopharm-announce-licensing-and-collaboration-agreement-to-develop-and-commercialize-lanifibranor-in-Greater-China.html
https://www.globenewswire.com/news-release/2022/07/07/2476242/0/en/Inventiva-announces-the-screening-of-the-first-patient-in-LEGEND-a-Phase-IIa-combination-trial-with-lanifibranor-and-empagliflozin-in-patients-with-NASH-and-T2D.html
https://www.globenewswire.com/news-release/2021/10/27/2322097/0/en/Inventiva-announces-the-design-of-LEGEND-a-Phase-IIa-combination-trial-with-lanifibranor-and-SGLT2-inhibitor-empagliflozin-in-patients-with-NASH-and-type-2-diabetes.html
https://www.globenewswire.com/news-release/2021/09/16/2298763/0/en/Inventiva-announces-major-recruitments-to-accelerate-the-development-of-lanifibranor-in-NASH.html
https://www.globenewswire.com/news-release/2021/09/08/2293792/0/en/Inventiva-announces-the-initiation-of-its-pivotal-Phase-III-clinical-trial-evaluating-lanifibranor-in-NASH.html
https://www.globenewswire.com/news-release/2020/11/10/2124178/0/en/Inventiva-receives-positive-FDA-feedback-to-advance-its-lead-drug-candidate-lanifibranor-into-pivotal-Phase-III-in-NASH.html
https://www.globenewswire.com/news-release/2020/06/15/2048284/0/en/Inventiva-s-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-Phase-IIb-NATIVE-clinical-trial-in-non-alcoholic-steatohepatitis-NASH.html
https://www.globenewswire.com/news-release/2020/05/25/2038188/0/en/Inventiva-secures-a-new-patent-for-lanifibranor-in-China-expanding-the-protection-of-its-lead-product-candidate.html
https://www.fiercebiotech.com/biotech/positive-phase-3-intercept-to-file-nash-drug-for-approval-while-inventiva-faces-a-setback
Market Place
Share 
